Dipeptidyl peptidase 4: A new link between diabetes mellitus and atherosclerosis?

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Silva Júnior, Wellington Santana Da ^a,b   Godoy Matos, Amélio Fernando De ^c   Kraemer Aguiar, Luiz Guilherme ^a,d  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d Faculty of Medical Sciences   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALOGLIPTIN; APROTININ; BRADYKININ; CHEMOKINE; CHROMOGRANIN; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOMORPHIN 1; ENDOMORPHIN 2; ENTEROSTATIN; EOTAXIN; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GROWTH HORMONE RELEASING FACTOR; INCRETIN; LINAGLIPTIN; METFORMIN; MORPHICEPTIN; NEUROPEPTIDE; NEUROPEPTIDE Y; PEPTIDE YY; PLACEBO; PROCALCITONIN; PROTEINASE; SAXAGLIPTIN; STROMAL CELL DERIVED FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1BETA;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC PATIENT; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLUCOSE TOLERANCE; HEART FAILURE; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COMPLICATION; DIABETES MELLITUS, TYPE 2; GENETICS; METABOLISM; PATHOLOGY;

ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; INCRETINS; INFLAMMATION;

EID: 84934957107     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/816164     Document Type: Review

References (85)

1. J. A. Beckman, M. A. Creager, and P. Libby, "Diabetes and atherosclerosis epidemiology, pathophysiology, and management, " Journal of theAmericanMedical Association, vol. 287, no. 19, pp. 2570-2581, 2002.
2. A. Natali and E. Ferrannini, "Endothelial dysfunction in type 2 diabetes, " Diabetologia, vol. 55, no. 6, pp. 1559-1563, 2012.
3. C. E. Tabit, W. B. Chung, N. M. Hamburg, and J. A. Vita, "Endothelial dysfunction in diabetesmellitus: molecularmechanisms and clinical implications, " Reviews in Endocrine and Metabolic Disorders, vol. 11, no. 1, pp. 61-74, 2010.
4. J. Nilsson, E. Bengtsson, G. N. Fredrikson, and H. Bjrkbacka, "Inflammation and immunity in diabetic vascular complications, " Current Opinion in Lipidology, vol. 19, no. 5, pp. 519-524, 2008.
5. R. A. Defronzo, "From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus, " Diabetes, vol. 58, no. 4, pp. 773-795, 2009.
6. A. F. Godoy-Matos, "The role of glucagonontype 2 diabetes at a glance, " Diabetology & Metabolic Syndrome, vol. 6, no. 1, article 91, 2014.
7. C. F. Deacon, E. Mannucci, and B. Ahrn, "Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-A review and meta analysis, " Diabetes, Obesity and Metabolism, vol. 14, no. 8, pp. 762-767, 2012.
8. M. B. Christensen, S. Calanna, J. J. Holst, T. Vilsbl, and F. K. Knop, "Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes, " The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 3, pp. E418-E426, 2014.
9. S. Cernea and I. Raz, "Therapy in the early stage: incretins, " Diabetes Care, vol. 34, supplement 2, pp. S264-S271, 2011.
10. J. J. Holst, "On the physiology of GIP and GLP-1, " Hormone and Metabolic Research, vol. 36, no. 11-12, pp. 747-754, 2004.
11. V. Matheeussen, L. Baerts, G. de Meyer et al., "Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries, " Biological Chemistry, vol. 392, no. 3, pp. 189-198, 2011.
12. J. Ryskj?, C. F. Deacon, R. D. Carr et al., "Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake, " European Journal of Endocrinology, vol. 155, no. 3, pp. 485-493, 2006.
13. E. Mannucci, L. Pala, S. Ciani et al., "Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetesmellitus, " Diabetologia, vol. 48, no. 6, pp. 1168-1172, 2005.
14. A. Venkatesham, M. Srinivas, D. R. Krishna, and P. Narayana, "Differential expression of Dipeptidyl peptidase-IV (DPP-IV) in Indian type-2 diabetic population, " Journal of Association of Physicians of India, vol. 57, no. 9, pp. 627-630, 2009.
15. S. A. Lee, Y. R. Kim, E. J. Yang et al., "CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus, " Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 6, pp. 2553-2561, 2013.
16. G. P. Fadini and A. Avogaro, "Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1, " Vascular Pharmacology, vol. 55, no. 1-3, pp. 10-16, 2011.
17. Y. Hu, H. Liu, R. W. Simpson, and A. E. Dear, "GLP-1-dependent and independent effects and molecularmechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells, " Molecular Biology Reports, vol. 40, no. 3, pp. 2273-2279, 2013.
18. M. R. Rizzo, M. Barbieri, R. Marfella, and G. Paolisso, "Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition, " Diabetes Care, vol. 35, no. 10, pp. 2076-2082, 2012.
19. E. Matteucci and O. Giampietro, "Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme, " Current Medicinal Chemistry, vol. 16, no. 23, pp. 2943-2951, 2009.
20. A.-M. Lambeir, C. Durinx, S. Scharp, and I. de Meester, "Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV, " Critical Reviews in Clinical Laboratory Sciences, vol. 40, no. 3, pp. 209-294, 2003.
21. D. Lamers, S. Famulla, N. Wronkowitz et al., "Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome, " Diabetes, vol. 60, no. 7, pp. 1917-1925, 2011.
22. W. B. White, C. P. Cannon, S. R. Heller et al., "Alogliptin after acute coronary syndrome in patients with type 2 diabetes, " The New Engl and Journal ofMedicine, vol. 369, no. 14, pp. 1327-1335, 2013.
23. B. M. Scirica, D. L. Bhatt, E. Braunwald et al., "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, "The New Engl and Journal ofMedicine, vol. 369, no. 14, pp. 1317-1326, 2013.
24. CAROLINA, "A multicentre, international, r and omised, parallel group, double blind study to evaluate cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk, " NCT01243424, 2014, http://clinicaltrials.gov/show/NCT01243424.
25. TECOS: a r and omized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control (NCT00790205), http://clinicaltrials .gov/show/NCT00790205.
26. J. Rosenstock, N. Marx, S. E. Kahn et al., "Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial, " Diabetes and Vascular Disease Research, vol. 10, no. 4, pp. 289-301, 2013.
27. J. B. Green, M. A. Bethel, S. K. Paul et al., "Rationale, design, and organization of a r and omized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease, " American Heart Journal, vol. 166, no. 6, pp. 983-989.e7, 2013.
28. D. J. Drucker, "Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action, " Diabetes Care, vol. 30, no. 6, pp. 1335-1343, 2007.
29. K. Aertgeerts, S. Ye, M. G. Tennant et al., "Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation, " Protein Science, vol. 13, no. 2, pp. 412-421, 2004.
30. M. V and erheyden, J. Bartunek, M. Goethals et al., "Dipeptidylpeptidase IV and B-Type natriuretic peptide. from bench to bedside, " Clinical Chemistry and Laboratory Medicine, vol. 47, no. 3, pp. 248-252, 2009.
31. G. S. Meneilly, H.-U. Demuth, C. H. S. McIntosh, and R. A. Pederson, "Effect of ageing and diabetes on glucosedependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose, " Diabetic Medicine, vol. 17, no. 5, pp. 346-350, 2000.
32. J. Korosi, C. H. S. McIntosh, R. A. Pederson et al., "Effect of aging and diabetes on the enteroinsular axis, " Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, vol. 56, no. 9, pp. M575-M579, 2001.
33. J. M. Lenhard, D. K. Croom, and D. T. Minnick, "Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments, " Biochemical and Biophysical Research Communications, vol. 324, no. 1, pp. 92-97, 2004.
34. J. R. Lindsay, N. A. Duffy, A. M. McKillop et al., "Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes, " Diabetic Medicine, vol. 22, no. 5, pp. 654-657, 2005.
35. B.D. Green, N. Irwin, N.A. Duffy, V. A. Gault, F. P. M. OHarte, and P. R. Flatt, "Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1, " European Journal of Pharmacology, vol. 547, no. 1-3, pp. 192-199, 2006.
36. M. Laakso, J. Zilinskaite, T. Hansen et al., "Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and /or impaired glucose tolerance in the EUGENE2 study, " Diabetologia, vol. 51, no. 3, pp. 502-511, 2008.
37. M. A. Abdul-Ghani and R. A. DeFronzo, "Pathophysiology of prediabetes, " Current Diabetes Reports, vol. 9, no. 3, pp. 193-199, 2009.
38. T. Zheng, Y. Gao, A. Baskota, T. Chen, X. Ran, and H. Tian, "Increased plasma DPP4 activity is predictive of prediabetes and type 2 diabetes onset in Chinese over a four-year period: result from the China National Diabetes and Metabolic Disorders Study, "The Journal of Clinical Endocrinology&Metabolism, vol. 99, no. 11, pp. E2330-E2334, 2014.
39. B. B. Dokken, L. R. la Bonte, G. Davis-Gorman, M. K. Teachey, N. Seaver, and P. F. McDonagh, "Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reducesmyocardial infarct size in rodents, " Hormone and Metabolic Research, vol. 43, no. 5, pp. 300-305, 2011.
40. B.B. Dokken, C. V. Piermarini, M. K. Teachey et al., "Glucagonlike peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 304, no. 4, pp. H538-H546, 2013.
41. M. H. Noyan-Ashraf, E. A. Shikatani, I. Schuiki et al., "A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity, " Circulation, vol. 127, no. 1, pp. 74-85, 2013.
42. E. Robinson, R. S. Cassidy, M. Tate et al., "Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix, " Basic Research in Cardiology, vol. 110, article 20, 2015.
43. S. Ravassa, J. Beaumont, A. Huerta et al., "Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study, " Free Radical Biology and Medicine, vol. 81, pp. 1-12, 2015.
44. S. Yamagishi, K. Fukami, and T. Matsui, "Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications, " Cardiovascular Diabetology, vol. 14, no. 1, article 2, 2015.
45. N. Tahara, S.-I. Yamagishi, M. Takeuchi et al., "Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans, " Clinical Biochemistry, vol. 46, no. 4-5, pp. 300-303, 2013.
46. Y. Ishibashi, T. Matsui, S. Maeda, Y. Higashimoto, and S.-I. Yamagishi, "Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulinlike growth factor II receptor, " Cardiovascular Diabetology, vol. 12, no. 1, article 125, 2013.
47. K. Augustyns, G. Bal, G. Thonus et al., "Theunique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors, " Current Medicinal Chemistry, vol. 6, no. 4, pp. 311-327, 1999.
48. L. Pala, E. Mannucci, A. Pezzatini et al., "Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells, " Biochemical and Biophysical Research Communications, vol. 310, no. 1, pp. 28-31, 2003.
49. L. Pala, A. Pezzatini, I. Dicembrini et al., "Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells, " Acta Diabetologica, vol. 49, supplement 1, pp. S59-S63, 2012.
50. A. Aiuti, I. J. Webb, C. Bleul, T. Springer, and J. C. Gutierrez-Ramos, "The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood, "The Journal of ExperimentalMedicine, vol. 185, no. 1, pp. 111-120, 1997.
51. T. Lapidot and O. Kollet, "The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2mnull mice, " Leukemia, vol. 16, no. 10, pp. 1992-2003, 2002.
52. G. P. Fadini, E. Boscaro, M. Albiero et al., "The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patientswith type 2 diabetes: possible role of stromal-derived factor-1alpha, " Diabetes Care, vol. 33, no. 7, pp. 1607-1609, 2010.
53. W. Jungraithmayr, I. De Meester, V. Matheeussen, L. Baerts, S. Arni, and W. Weder, "CD26/DPP-4 inhibition recruits regenerative stemcells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation, " European Journal of Cardio-Thoracic Surgery, vol. 41, no. 5, pp. 1166-1173, 2012.
54. P. C. M. van Poppel, M. G. Netea, P. Smits, and C. J. Tack, "Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes, " Diabetes Care, vol. 34, no. 9, pp. 2072-2077, 2011.
55. W. Takasawa, K. Ohnuma, R. Hatano, Y. Endo, N.H. Dang, and C. Morimoto, "Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines, " Biochemical and Biophysical Research Communications, vol. 401, no. 1, pp. 7-12, 2010.
56. J. Zhong, X. Rao, J. Deiuliis et al., "A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation, " Diabetes, vol. 62, no. 1, pp. 149-157, 2013.
57. P. E. Scherer, "Adipose tissue: from lipid storage compartment to endocrine organ, " Diabetes, vol. 55, no. 6, pp. 1537-1545, 2006.
58. S. Galic, J. S. Oakhill, and G. R. Steinberg, "Adipose tissue as an endocrine organ, "Molecular and Cellular Endocrinology, vol. 316, no. 2, pp. 129-139, 2010.
59. G. I. Shulman, "Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease, " New Engl and Journal ofMedicine, vol. 371, no. 12, pp. 1131-1141, 2014.
60. H. Sell, M. Blher, N. Klting et al., "Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro, " Diabetes Care, vol. 36, no. 12, pp. 4083-4090, 2013.
61. M. Monami, B. Ahrn, I. Dicembrini, and E. Mannucci, "Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: ametaanalysis of r and omized clinical trials, " Diabetes, Obesity and Metabolism, vol. 15, no. 2, pp. 112-120, 2013.
62. P. Craddy, H. J. Palin, and K. I. Johnson, "Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison, " Diabetes Therapy, vol. 5, no. 1, pp. 1-41, 2014.
63. E. Bosi, R. P. Camisasca, C. Collober, E. Rochotte, and A. J. Garber, "Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin, " Diabetes Care, vol. 30, no. 4, pp. 890-895, 2007.
64. R. A. DeFronzo, M. N. Hissa, A. J. Garber et al., "The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone, " Diabetes Care, vol. 32, no. 9, pp. 1649-1655, 2009.
65. T. Forst, B. Uhlig-Laske, A. Ring et al., "Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes, " DiabeticMedicine, vol. 27, no. 12, pp. 1409-1419, 2010.
66. E. J. Rhee, W. Y. Lee, K. W. Min et al., "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patientswith type 2 diabetes inadequately controlled with metformin alone, " Diabetes, Obesity and Metabolism, vol. 15, no. 6, pp. 523-530, 2013.
67. B. Gke, B. Gallwitz, J. Eriksson, ? A. Hellqvist, I. Gause-Nilsson, and D1680C00001 Investigators, "Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week r and omised controlled trial, " International Journal of Clinical Practice, vol. 64, no. 12, pp. 1619-1631, 2010.
68. C. Filozof and J.-F. Gautier, "A comparison of efficacy and safety of vildagliptin and gliclazide in combination withmetformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, r and omized study, " DiabeticMedicine, vol. 27, no. 3, pp. 318-326, 2010.
69. G. Bolli, F. Dotta, E. Rochotte, and S. E. Cohen, "Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, r and omized, double-blind study, " Diabetes, Obesity and Metabolism, vol. 10, no. 1, pp. 82-90, 2008.
70. A. Sicras-Mainar and R. Navarro-Artieda, "Economic impact of combiningmetformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in Spanish patients, " Diabetes & Metabolism Journal, vol. 39, no. 1, pp. 74-81, 2015.
71. D. M. Nathan, J. B. Buse, S. E. Kahn et al., "Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE), " Diabetes Care, vol. 36, no. 8, pp. 2254-2261, 2013.
72. R. Frederich, J. H. Alex and er, F. T. Fiedorek et al., "A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes, " Postgraduate Medicine, vol. 122, no. 3, pp. 16-27, 2010.
73. O. E. Johansen, D. Neubacher, M. von Eynatten, S. Patel, and H.-J. Woerle, "Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-Analysis of a phase 3 programme, " Cardiovascular Diabetology, vol. 11, article 3, 2012.
74. A. Schweizer, S. Dejager, J. E. Foley, A. Couturier, M. Ligueros-Saylan, and W. Kothny, "Assessing the cardio-cerebrovascular safety of vildagliptin: meta-Analysis of adjudicated events from a large Phase III type 2 diabetes population, " Diabetes, Obesity and Metabolism, vol. 12, no. 6, pp. 485-494, 2010.
75. S. S. Engel, E. Round, G. T. Golm, K. D. Kaufman, and B. J. Goldstein, "Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies, " Diabetes Therapy, vol. 4, no. 1, pp. 119-145, 2013.
76. H. R. Patil, F. J. Al Badarin, H. A. Al Shami et al., "Meta-Analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus, " The American Journal of Cardiology, vol. 110, no. 6, pp. 826-833, 2012.
77. J. R. Ussher and D. J. Drucker, "Cardiovascular biology of the incretin system, " Endocrine Reviews, vol. 33, no. 2, pp. 187-215, 2012.
78. D. J. Hausenloy, H. J. Whittington, A. M. Wynne et al., "Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner, " Cardiovascular Diabetology, vol. 12, no. 1, article 154, 2013.
79. Y. Terawaki, T. Nomiyama, T. Kawanami et al., "Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury, " Cardiovascular Diabetology, vol. 13, no. 1, article 154, 2014.
80. B. M. Scirica, I. Raz, M. A. Cavender et al., "Abstract 17503: outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: analyses of the SAVORTIMI 53 study, " Circulation, vol. 128, Article IDA17503, 2013.
81. E. St and l, "Saxagliptin, alogliptin, and cardiovascular outcomes, " The New Engl and Journal of Medicine, vol. 370, no. 5, article 484, 2014.
82. G. Savarese, P. Perrone-Filardi, C. DAmore et al., "Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-Analysis, " International Journal of Cardiology, vol. 181, pp. 239-244, 2015.
83. E. St and l, "Saxagliptin, alogliptin, and cardiovascular outcomes, " The New Engl and Journal of Medicine, vol. 370, no. 5, pp. 483-484, 2014.
84. J. K. Devin, M. Pretorius, H. Nian, C. Yu, F. T. Billings IV, and N. J. Brown, "Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition, " Hypertension, vol. 63, no. 5, pp. 951-957, 2014.
85. I. Dicembrini and E. Mannucci, "Risk of myocardial infarction in trials with dipeptidyl peptidase-4 inhibitors: is duration of study a real issue?" International Journal of Cardiology, 2015.